Viking Therapeutics
9920 Pacific Heights Blvd, Suite 350
San Diego
California
92121
United States
Tel: 858-550-7810
Website: http://www.vikingtherapeutics.com/
Email: info@vikingtheraputics.com
218 articles about Viking Therapeutics
-
Viking Therapeutics to Participate in Upcoming Investor Conferences on March 2020
2/24/2020
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in four upcoming investor conferences.
-
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
2/19/2020
Conference Call Scheduled for Wednesday, February 26 at 4:30 p.m. Eastern Time
-
Viking Therapeutics to Present at Biotech Showcase 2020
1/6/2020
Viking Therapeutics, Inc. announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at Biotech Showcase™ 2020, being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.
-
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
11/19/2019
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH)
-
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/5/2019
Viking Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2019, and provided an update on its clinical pipeline and other corporate developments.
-
Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
10/31/2019
Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time
-
Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
9/25/2019
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will deliver a corporate presentation at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019 in New York, NY.
-
For years, companies have struggled to develop treatments for non-alcoholic fatty liver disease (NAFLD), a disease that is growing across the world and is predicted to become the main cause of chronic liver problems and the need for liver transplantation.
-
Viking Therapeutics to Participate in Upcoming Investor Conferences - Aug. 28, 2019
8/28/2019
Viking Therapeutics, Inc. announced that the company will participate in two upcoming investor conferences.
-
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
8/1/2019
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June 30, 2019, and provided an update on its clinical pipeline and other corporate developments.
-
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
7/25/2019
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2019, after the market close on Thursday, August 1, 2019.
-
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
7/2/2019
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Kathy Rouan, Ph.D., to its board of directors
-
Viking Therapeutics to Participate in Upcoming Investor Conferences - May 28, 2019
5/28/2019
Viking Therapeutics, Inc. announced that the company will participate in three upcoming investor conferences.
-
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
5/2/2019
Conference call scheduled for 4:30 p.m. ET today
-
Viking Therapeutics to Participate in Upcoming Investor Conferences - April 30, 2019
4/30/2019
Viking Therapeutics, Inc. announced that the company will participate in two upcoming investor conferences.
-
Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
4/25/2019
Conference Call Scheduled for Thursday, May 2 at 4:30 p.m. Eastern Time
-
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
4/11/2019
Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8%
-
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
-
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
4/4/2019
Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm
-
Viking Therapeutics to Participate in Upcoming Investor Conferences - March 28, 2019
3/28/2019
Viking Therapeutics, Inc. announced that the company will participate in two upcoming investor conferences.